The European Court of Justice has stated that cannabidiol (CBD) isn’t a narcotic and “does not appear to have any psychotropic effect or harmful effect on human health”.
The court made the decision while presiding over a recent case concerning a French vaping company, KanaVape. See more about the case at the end of this article
Derived from either hemp or cannabis, CBD is an active but non-psychoactive compound that’s taken the wellness industry by storm in recent years, with a host of CBD-based treatments, tinctures, creams, food and drinks.
It’s believed the ingredient is capable of helping to treat stress and anxiety, inflammation, joint pain, muscle soreness and insomnia, as well as children’s epilepsy.
But, because another part of the marijuana plant – tetrahydrocannabinol (THC) – can cause a psychotropic effect, it was banned in the 1930s and a stigma was attached to the plant.
However, CBD derived from hemp (a variety of cannabis) contains a very low THC concentration – usually 0.3 per cent or less – and tends to be the most typically-used strain.
The news is a win for European CBD suppliers and the wellness industry, but Liz Terry, editorial director of Spa Business and Spa Business insider, believes spa operators should still proceed with caution.
She said: “Operators and suppliers need to tread carefully when it comes to offering CBD treatments, to…
